Galectin Therapeutics (STU:PHPN) Cyclically Adjusted PB Ratio: (As of Sep. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PHPN Galectin Therapeutics Inc STU:PHPN
25 GF Score
Price €3.32
! 5 Warning Signs
View Full Analysis

What is Galectin Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Galectin Therapeutics  (STU:PHPN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Galectin Therapeutics Cyclically Adjusted PB Ratio Related Terms


Galectin Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Galectin Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galectin Therapeutics Cyclically Adjusted PB Ratio Chart

Galectin Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.39 5.00 11.58 0.00 0.00

Galectin Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:PHPN vs XFOR, LXEO, LRMR: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Galectin Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galectin Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galectin Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Galectin Therapeutics's Cyclically Adjusted PB Ratio falls into.


STU:PHPN
25GF Score
Galectin Therapeutics Inc STU:PHPN
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galectin Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Galectin Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Galectin Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-1.834/333.9520*333.9520
=-1.834

Current CPI (Jun. 2026) = 333.9520.

Galectin Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 0.111 241.428 0.154
201612 0.088 241.432 0.122
201703 0.018 243.801 0.025
201706 -0.079 244.955 -0.108
201709 -0.149 246.819 -0.202
201712 -0.181 246.524 -0.245
201803 -0.136 249.554 -0.182
201806 0.017 251.989 0.023
201809 0.000 252.439 0.000
201812 -0.043 251.233 -0.057
201903 0.089 254.202 0.117
201906 0.766 256.143 0.999
201909 0.764 256.759 0.994
201912 0.679 256.974 0.882
202003 0.647 258.115 0.837
202006 0.544 257.797 0.705
202009 0.438 260.280 0.562
202012 0.314 260.474 0.403
202103 0.238 264.877 0.300
202106 0.211 271.696 0.259
202109 0.102 274.310 0.124
202112 0.005 278.802 0.006
202203 -0.128 287.504 -0.149
202206 -0.281 296.311 -0.317
202209 -0.422 296.808 -0.475
202212 -0.543 296.797 -0.611
202303 -0.693 301.836 -0.767
202306 -0.821 305.109 -0.899
202309 -0.811 307.789 -0.880
202312 -0.914 306.746 -0.995
202403 -1.092 312.332 -1.168
202406 -1.264 314.175 -1.344
202409 -1.362 315.301 -1.443
202412 -1.610 315.605 -1.704
202503 -1.675 319.799 -1.749
202506 -1.588 322.561 -1.644
202509 -1.661 324.800 -1.708
202512 -1.677 324.054 -1.728
202603 -1.745 330.213 -1.765
202606 -1.834 333.952 -1.834

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Galectin Therapeutics Business Description

Other Exchanges GALT:USA
Address 4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
25GF Score

Get the complete analysis for STU:PHPN

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.32
Price